News and Announcements
Analytica Limited Eyes $1.5 Million in New Renounceable Offer
- Published September 29, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Analytica has prepared a Prospectus, containing the details of the Entitlement Offer, and has sent this to eligible shareholders by September 28.
- Analytica Limited is set to raise $1.593 million as it undertakes a renounceable pro-rata entitlement offer to eligible shareholders with a registered address in New Zealand or Australia.
- Eligible shareholders can trade their rights to subscribe for new shares.
Analytica Limited expects to raise $1.593 million as it undertakes a renounceable pro-rata entitlement offer to eligible shareholders with a registered address in New Zealand or Australia. Shareholders with addresses outside of the two areas are considered ineligible shareholders.
The company decided not to extend the offer to ineligible shareholders considering the complexity, legal costs and requirements of specific authorities in other jurisdictions.
The entitlement offer, with an offer price of 0.5 cents for every new share, consists of one share for every eight existing shares held by a shareholder as of 7 p.m. on September 21.
Shareholders who intend to apply for the entitlement offer can opt for two Attaching Options: a share exercisable at 0.5 cents expiring on January 31, 2018, or a share exercisable at 0.5 cents expiring on May 31, 2018.
Eligible shareholders can apply for Additional Shares, or shares not subscribed by the other eligible shareholders. However, its allocation will be at the discretion of the directors and limited only to the number of shortfall shares. Successful applications will also have a dig at the Attaching Options.
The entitlements for the successful applicants under the offer are renounceable. Rights of the shareholders to subscribe for new shares and also the Attaching Options the ASX can be traded on ASX to any party from September 26 to October 5, the period stated for the rights trading period.
Analytica will add the fresh funds raised to its general working capital and use it to fund the PeriCoachTM System development. The company has 2,549,136,332 shares currently on issue and 318,642,042 shares under the offer of entitlement.
Analytica has prepared a Prospectus which contains all the offers being made. It also includes all details pertaining to the entitlement offer including the expenses related to the offer and the use of its proceeds.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
